



Identification of *Candida parapsilosis Sensu Lato* in Pediatric Patients and Antifungal Susceptibility Testing

Maria Emilia Cattana,^{a*} Catiana Dudiuk,^b Mariana Fernández,^a Florencia Rojas,^a Liliana Alegre,^a Susana Córdoba,^c Guillermo Garcia-Effron,^b Gustavo Giusiano^a

Área Micología, Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Argentina^a; Laboratorio de Micología y Diagnóstico Molecular, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina^b; Laboratorio de Antifúngicos, Departamento de Micología, INEI, ANLIS "Dr. Carlos Malbrán," Ciudad Autónoma de Buenos Aires, Argentina^c

ABSTRACT A total of 59 *Candida parapsilosis sensu stricto* and 1 *Candida orthopsilosis* recovered from catheters and blood cultures of pediatric patients from the north-eastern region of Argentina were studied. Susceptibility to azoles, amphotericin B, and echinocandins was tested by the broth microdilution method. According to CLSI clinical breakpoints, >91% of the strains were azole susceptible, whereas 15% showed high amphotericin B MICs.

KEYWORDS *C. orthopsilosis*, *C. parapsilosis sensu stricto*, PCR-REA, amphotericin B, blood culture, echinocandin

Candidemia is the fourth most prevalent nosocomial bloodstream infection and the most frequent nosocomial fungal infection (1–3). *Candida parapsilosis sensu lato* is the second most frequently isolated species from blood in Asia, Latin America, and some European countries, surpassing the *Candida albicans* frequency in some pediatric hospitals (4–10). *C. parapsilosis sensu lato* includes 3 closely related species: *C. parapsilosis sensu stricto*, *Candida orthopsilosis*, and *Candida metapsilosis* (11).

The aims of this study were to determine the prevalence of the *C. parapsilosis* species complex as a candidemia agent in pediatric patients from the northeastern region of Argentina and to evaluate its susceptibility.

Between 2009 and 2014, 60 isolates from 40 neonates (<1 month old) and pediatric patients (<6 years old) admitted to Resistencia and Corrientes, Argentina, hospitals were studied. All patients had proved invasive fungal disease according to EORTC/MSG (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group) criteria (12). Twenty-nine isolates were recovered from blood and 31 from catheters with positive blood cultures. All isolates were referred for identification and antifungal susceptibility studies to the Mycology Department of the Instituto de Medicina Regional, Universidad Nacional del Nordeste, and deposited in its culture collection.

The isolates were identified as *C. parapsilosis sensu lato* using API ID 32C (bio-Mérieux, Marcy l'Etoile, France) and micromorphology (13). Molecular identification was performed using a PCR-based restriction endonuclease analysis (PCR-REA), where an *FKS1* region was amplified by PCR and subsequently digested with EcoRI (14). DNA extraction was performed following the protocol of Bosco-Borgeat et al. (15).

The *in vitro* antifungal activity of fluconazole (FLC), voriconazole (VRC), and anidulafungin (ANF) (Pfizer, USA); caspofungin (CSF) (Merck & Co., USA); and itraconazole (ITC) and amphotericin B (AMB) (Sigma-Aldrich) were evaluated according to CLSI documents M27-A3 and M27-S4 (16, 17). All but one isolate were molecularly identified

Received 29 December 2016 Returned for modification 21 February 2017 Accepted 30 April 2017

Accepted manuscript posted online 8 May 2017

Citation Cattana ME, Dudiuk C, Fernández M, Rojas F, Alegre L, Córdoba S, García-Effron G, Giusiano G. 2017. Identification of *Candida parapsilosis sensu lato* in pediatric patients and antifungal susceptibility testing. *Antimicrob Agents Chemother* 61:e02754-16. <https://doi.org/10.1128/AAC.02754-16>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Maria Emilia Cattana, memiliacattana@yahoo.com.ar.

* Present address: Área Micología, Instituto de Medicina Regional, Universidad Nacional del Nordeste, Chaco, Argentina.

TABLE 1 Geometric mean, concentration range, MIC₅₀, and MIC₉₀ obtained from 59 isolates of *C. parapsilosis sensu stricto*

| Drug ^a | Geometric mean (μg/ml) | Range (μg/ml) | MIC ₅₀ | MIC ₉₀ | Susceptibility (% [n]) ^b | | | | |
|-------------------|------------------------|---------------|-------------------|-------------------|-------------------------------------|---------------------|-----------|---------|----------------|
| | | | | | ECV | | CBP | | |
| | | | | | WT | Non-WT ^d | S | SDD/I | R ^d |
| AMB ^c | 1.00 | 0.50–2.00 | 1 | 2 | 100 (59) | | | | |
| FLC | 1.50 | 0.25–4.00 | 2 | 2 | | | 91.5 (54) | 8.5 (5) | |
| ITC ^c | 0.10 | ≤0.03–0.25 | ≤0.03 | ≤0.03 | 100 (59) | | | | |
| VRC | 0.06 | ≤0.03–0.125 | ≤0.03 | 0.06 | | | 100 (59) | | |
| ANF | 1.10 | 0.015–4.00 | 1 | 2 | | | 97 (57) | 3 (2) | |
| CSF | 1.00 | 0.125–2.00 | 1 | 1 | | | 100 (59) | | |

^aAMB, amphotericin B; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; CSF, caspofungin; ANF, anidulafungin.

^bECV, epidemiological cutoff values; CBP, clinical breakpoint; WT, wild type; S, susceptible; SDD, susceptible dose dependent (for azole drugs); I, intermediate (for ANF and CSF); R, resistant.

^cNo clinical breakpoints are available. Thus, epidemiological cutoff values were used as susceptibility criteria (18).

^dNo resistant or non-wild type isolate was obtained.

as *C. parapsilosis sensu stricto*. The single *C. orthopsilosis* isolate identified showed the following MIC values: AMB 1 μg/ml, FLC 1 μg/ml, ITC 0.06 μg/ml, VRC 0.06 μg/ml, ANF 0.5 μg/ml, and CSF 1 μg/ml. For AMB, *C. parapsilosis sensu stricto* isolates showed a narrow range of MIC values (geometric mean [GM], 1 μg/ml; range, 0.5 to 2 μg/ml) and an unexpectedly high MIC₉₀ of 2 μg/ml, with nine strains showing AMB MIC values of 2 μg/ml (Table 1). Azoles and echinocandins showed good activity. The majority of the strains showed a low FLC MIC, and only five strains (8.5%) had MIC values that were considered susceptible dose dependent (SDD). All of the strains were susceptible to VRC (range, ≤0.03 to 0.125 μg/ml) and considered wild type when ITC was tested (MIC GM, 0.1 μg/ml) following the clinical breakpoints and epidemiological cutoff values, respectively (18). For the echinocandins, MIC values were lower for CSF than for ANF. However, all of the strains were considered susceptible to CSF, and all but two were susceptible to ANF (considered intermediate) (Table 1).

Spanish studies in neonates and pediatric populations showed a *C. parapsilosis sensu stricto* prevalence of between 72% and 91% and a *C. orthopsilosis* presence of between 9% and 27% (6, 19, 20). Moreover, in a global study, the rate of *C. orthopsilosis* in South America was 10.9%, with variations between 16.5% in Venezuela and 3.1% in Argentina (1, 6, 19, 20). Only one *C. orthopsilosis* isolate (2%) and no *C. metapsilosis* isolate was found in our study population.

Most studies report *C. parapsilosis sensu stricto* as the species in the complex with the highest MICs to antifungal agents (19–21). Although an AMB tolerance in *C. parapsilosis sensu lato* isolates has been described (8, 22, 23), most authors reported an AMB MIC₉₀ of <1 μg/ml (1, 6, 19–21, 24–28). In our study, nine isolates (15%) had an MIC of 2 μg/ml, which was similar to the MICs obtained by Lockhart et al. (20) and Cantón et al. (21).

Echinocandins were not used as treatment or prophylaxis in our patients. However, we obtained high CSF MIC values. To circumvent the described problems related to CSF susceptibility testing (27), ANF susceptibility was added to the study. As described before, wide MIC ranges were found (0.015 to 4 μg/ml for ANF and 0.125 to 2 μg/ml for CSF) (19, 21, 29–34). Also, the MIC₉₀ for ANF was similar to those obtained by other authors (1, 6, 19–21, 24–28, 30).

Regarding azoles, FLC presented the highest MIC ranges (0.25 to 4 μg/ml). However, 90% of the isolates were susceptible and showed MIC values similar to those presented elsewhere (1, 6, 19–21, 24–28, 30). Five isolates were categorized FLC-SDD (MIC, 4 μg/ml), and two of them had the highest ITC and VRC MIC values in this series (0.25 and 0.125 μg/ml, respectively), probably due to cross-tolerance mechanisms among azoles (35). No differences in susceptibility profiles were observed in patients with more than one isolate, except for one patient on FLC treatment with six successive isolates (2 from catheter and 4 from blood). The last isolate recovered from blood was categorized as FLC-SDD, whereas the previous five isolates were susceptible to all azoles.

A high percentage of the studied strains were susceptible to FLC, but an unexpectedly high number of isolates showed high AMB MIC values. These are important results for our region, since FLC and AMB are sometimes the only drugs available in most Latin American hospitals due to economic factors.

No conclusions can be drawn about the *C. orthopsilosis* antifungal susceptibility profile because only one strain was isolated; however, we observed low MICs to all the tested drugs. The discrimination of cryptic species within the *C. parapsilosis* species complex would not have a considerable clinical utility. However, surveillance is important to determine the epidemiology of this complex, observe changes in species distribution, and detect resistant strains, especially in pediatric patients whose treatment options are limited. To our knowledge, this is the first study in Argentina on the prevalence of *C. parapsilosis sensu lato* and its susceptibility profile in neonates and pediatric patients with candidemia.

ACKNOWLEDGMENT

We have no conflicts of interest to declare.

REFERENCES

- Blyth CC, Chen SC, Slavin M, Serena C, Nguyen Q, Marriott D, Ellis D, Meyer W, Sorrell TC. 2009. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. *Pediatrics* 123:1360–1368. <https://doi.org/10.1542/peds.2008-2055>.
- Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis* 41:1232–1239. <https://doi.org/10.1086/496922>.
- Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. *Crit Rev Microbiol* 36:1–53. <https://doi.org/10.3109/10408410903241444>.
- Singh N. 2001. Changing spectrum of invasive candidiasis and its therapeutic implications. *Clin Microbiol Infect* 7(Suppl 2):S1–S7.
- Trofa D, Gácsér A, Nosanchuk JD. 2008. *Candida parapsilosis*, an emerging fungal pathogen. *Clin Microbiol Rev* 21:606–625. <https://doi.org/10.1128/CMR.00013-08>.
- Cantón E, Pemán J, Quindós G, Eraso E, Miranda-Zapico I, Álvarez M, Merino P, Campos-Herrero I, Marco F, de la Pedrosa EGG, Yagüe G, Guna R, Rubio C, Miranda C, Pazos C, Velasco D. 2011. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* isolated from patients with candidemia. *Antimicrob Agents Chemother* 55:5590–5596. <https://doi.org/10.1128/AAC.00466-11>.
- Ruiz LS, Khouri S, Hahn RC, da Silva EG, de Oliveira VKP, Gandra RF, Paula CR. 2013. Candidemia by species of the *Candida parapsilosis* complex in children's hospital: prevalence, biofilm production and antifungal susceptibility. *Mycopathologia* 175:231–239. <https://doi.org/10.1007/s11046-013-9616-5>.
- Santos PE, Córdoba S, Carrillo-Muñoz A, Rodero L, Ruboglio E, Soria M. 2010. Epidemiology of fungaemia in a paediatric hospital of high complexity. *Rev Iberoam Micol* 27:200–202. <https://doi.org/10.1016/j.riam.2010.07.002>.
- Neu N, Malik M, Lunding A, Whittier S, Alba L, Kubin C, Saiman L. 2009. Epidemiology of candidemia at a children's hospital, 2002 to 2006. *Pediatr Infect Dis J* 28:806–809. <https://doi.org/10.1097/INF.0b013e3181a0d78d>.
- Córdoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O, Isla G, Davel G. 2011. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. *Rev Argent Microbiol* 43:176–185.
- Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC. 2005. *Candida orthopsilosis* and *Candida metapsilosis* spp. nov. to replace *Candida parapsilosis* groups II and III. *J Clin Microbiol* 43:284–292. <https://doi.org/10.1128/JCM.43.1.284-292.2005>.
- Pauw B De, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. *Clin Infect Dis* 46:1813–1821. <https://doi.org/10.1086/588660>.
- Jitsurong S, Kiamsiri S, Pattararangrong N. 1993. New milk medium for germ tube and chlamydoconidia production by *Candida albicans*. *Mycopathologia* 123:95–98. <https://doi.org/10.1007/BF01365086>.
- García-Effron G, Canton E, Pemán J, Dilger A, Romá E, Perlin DS. 2011. Assessment of two new molecular methods for identification of *Candida parapsilosis sensu lato* species. *J Clin Microbiol* 49:3257–3261. <https://doi.org/10.1128/JCM.00508-11>.
- Bosco Borgeat M, Mazza M, Refojo N, Taverna M. 2011. Tipificación molecular de especies del género *Cryptococcus*, p 164–166. In Merino L, Giusiano G (ed), *Manual de métodos moleculares para estudios microbiológicos*. Asociación Argentina de Microbiología, Buenos Aires, Argentina.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
- Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of *Candida* spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. *J Clin Microbiol* 50:2846–2856. <https://doi.org/10.1128/JCM.00937-12>.
- García-Rodríguez J, Cantón E, Pemán J, Alvarez M, Ezpeleta G, Gómez-Nieto A, Iglesias I, Martín-Mazuelos E, Ramírez-de Ocariz I, Rezusta A, Royo-García G, Grupo de Estudio FUNGEMYCA. 2013. Incidencia etaria y geográfica y patrón de sensibilidad a los antifúngicos de las especies de *Candida* causantes de candidemia en la población pediátrica española. *Enferm Infecc Microbiol Clin* 31:363–368. <https://doi.org/10.1016/j.eimc.2012.09.018>.
- Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of the newly described species *Candida orthopsilosis* and *Candida metapsilosis* in comparison to the closely related species *Candida parapsilosis*. *J Clin Microbiol* 46:2659–2664. <https://doi.org/10.1128/JCM.00803-08>.
- Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream *Candida* species. *Diagn Microbiol Infect Dis* 45:203–206. [https://doi.org/10.1016/S0732-8893\(02\)00525-4](https://doi.org/10.1016/S0732-8893(02)00525-4).
- de Toro M, Torres MJ, Maite R, Aznar J. 2011. Characterization of *Candida*

- parapsilosis* complex isolates. Clin Microbiol Infect 17:418–424. <https://doi.org/10.1111/j.1469-0691.2010.03302.x>.
23. Gonçalves SS, Amorim CS, Nucci M, Padovan ACB, Briones MRS, Melo ASA, Colombo AL. 2010. Prevalence rates and antifungal susceptibility profiles of the *Candida parapsilosis* species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 16:885–887. <https://doi.org/10.1111/j.1469-0691.2009.03020.x>.
 24. Ziccardi M, Souza LOP, Gandra RM, Galdino ACM, Baptista ARS, Nunes APF, Ribeiro MA, Branquinha MH, Santos ALS. 2015. *Candida parapsilosis* (*sensu lato*) isolated from hospitals located in the Southeast of Brazil: species distribution, antifungal susceptibility and virulence attributes. Int J Med Microbiol 305:848–859. <https://doi.org/10.1016/j.ijmm.2015.08.003>.
 25. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, Gow NAR, Jones BL. 2007. One year prospective survey of *Candida* bloodstream infections in Scotland. J Med Microbiol 56:1066–1075. <https://doi.org/10.1099/jmm.0.47239-0>.
 26. Treviño-Rangel R, Garza-González E, González G, Bocanegra-García V, Laca JM, González GM. 2012. Molecular characterization and antifungal susceptibility of the *Candida parapsilosis* species complex of clinical isolates from Monterrey, Mexico. Med Mycol 50:781–784. <https://doi.org/10.3109/13693786.2012.675526>.
 27. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SRBS, St-Germain G, Szesz MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for *Candida* spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 57:5836–5842. <https://doi.org/10.1128/AAC.01519-13>.
 28. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K. 2011. National surveillance of fungemia in Denmark (2004) to (2009). J Clin Microbiol 49:325–334. <https://doi.org/10.1128/JCM.01811-10>.
 29. Silva A, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. 2009. Prevalence, distribution, and antifungal susceptibility profiles of *Candida parapsilosis*, *C. orthopsilosis*, and *C. metapsilosis* in a tertiary care hospital. J Clin Microbiol 47:2392–2397. <https://doi.org/10.1128/JCM.02379-08>.
 30. Seidenfeld SM, Cooper BH, Smith JW, Luby JP, Mackowiak PA. 1983. Amphotericin b tolerance: a characteristic of *Candida parapsilosis* not shared by other candida species. J Infect Dis 147:116–119. <https://doi.org/10.1093/infdis/147.1.116>.
 31. González GM, Treviño-Rangel RDJ, Palma-Nicolás JP, Martínez C, Lez JGG, Ayala J, Caballero A, Morfín-Otero R, Rodríguez-Noriega E, Velarde F, Ascencio EP, Tinoco JC, Vázquez JA, Cano MA, León-Sicairos N, Lez RG, Rincón J, Elías MA, Bonifaz A. 2013. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. J Antimicrob Chemother 68:2847–2851. <https://doi.org/10.1093/jac/dkt283>.
 32. Chen Y-C, Lin Y-H, Chen K-W, Lii J, Teng H-J, Li S-Y. 2010. Molecular epidemiology and antifungal susceptibility of *Candida parapsilosis sensu stricto*, *Candida orthopsilosis*, and *Candida metapsilosis* in Taiwan. Diagn Microbiol Infect Dis 68:284–292. <https://doi.org/10.1016/j.diagmicrobio.2010.07.004>.
 33. Ghannoum MA, Chen A, Buhari M, Chandra J, Mukherjee PK, Baxa D, Golembieski A, Vazquez JA. 2009. Differential *in vitro* activity of anidulafungin, caspofungin and micafungin against *Candida parapsilosis* isolates recovered from a burn unit. Clin Microbiol Infect 15:274–279. <https://doi.org/10.1111/j.1469-0691.2008.02660.x>.
 34. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, Almirante B, Pahissa A, Rodriguez-Tudela JL, Cuenca-Estrella M. 2008. Prevalence and susceptibility profile of *Candida metapsilosis* and *Candida orthopsilosis*: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509. <https://doi.org/10.1128/AAC.01595-07>.
 35. Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of *Candida albicans* genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405–416. <https://doi.org/10.1099/00221287-143-2-405>.